Advanced

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

Papp, KA; Guenther, L; Boyden, B; Larsen, FG; Harvima, RJ; Guilhou, JJ; Kaufmann, R; Rogers, S; van de Kerkhof, PCM and Hanssen, LI, et al. (2003) In Journal of American Academy of Dermatology 48(1). p.48-54
Abstract
Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective. We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone clipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients... (More)
Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective. We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone clipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients with psoriasis vulgaris amenable to topical treatment. Results. The mean percentage reduction in PASI from baseline to end of treatment was 73.2% in the combination group (n = 301), 48.8% in the calcipotriene group (n = 308), 63.1% in the betamethasone dipropionate group (n = 312) and 28.8% in the new vehicle group (n = 107), (P < .001). The mean percentage reduction in PASI during the first week was 48.1%, 28.4%, 41.4%, and 21.5%, respectively (P < .001). Conclusion: A combination product of calcipotriene 50 mug/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of American Academy of Dermatology
volume
48
issue
1
pages
48 - 54
publisher
Elsevier
external identifiers
  • pmid:12522370
  • wos:000180348600006
  • scopus:0037231470
ISSN
0190-9622
DOI
10.1067/mjd.2003.130
language
English
LU publication?
yes
id
3d422e95-a465-462a-8b22-d7134223c5ee (old id 319766)
date added to LUP
2007-09-20 08:25:12
date last changed
2017-07-02 03:41:50
@article{3d422e95-a465-462a-8b22-d7134223c5ee,
  abstract     = {Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective. We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone clipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients with psoriasis vulgaris amenable to topical treatment. Results. The mean percentage reduction in PASI from baseline to end of treatment was 73.2% in the combination group (n = 301), 48.8% in the calcipotriene group (n = 308), 63.1% in the betamethasone dipropionate group (n = 312) and 28.8% in the new vehicle group (n = 107), (P &lt; .001). The mean percentage reduction in PASI during the first week was 48.1%, 28.4%, 41.4%, and 21.5%, respectively (P &lt; .001). Conclusion: A combination product of calcipotriene 50 mug/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris.},
  author       = {Papp, KA and Guenther, L and Boyden, B and Larsen, FG and Harvima, RJ and Guilhou, JJ and Kaufmann, R and Rogers, S and van de Kerkhof, PCM and Hanssen, LI and Tegner, Eva and Burg, G and Talbot, D and Chu, A},
  issn         = {0190-9622},
  language     = {eng},
  number       = {1},
  pages        = {48--54},
  publisher    = {Elsevier},
  series       = {Journal of American Academy of Dermatology},
  title        = {Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis},
  url          = {http://dx.doi.org/10.1067/mjd.2003.130},
  volume       = {48},
  year         = {2003},
}